Sterinova

SECTION 2: Hazards identification

1999/45/EC Main Hazards: Classification according to the European Directive on Classification of Hazardous Preparations 1999/45/EC (Conventional Method) Contact with combustible materials may cause fire Irritating to eyes and respiratory system Short-Term Exposure (Acute) Inhalation: This material contained in this tablet in solid form is not expected to produce respiratory effects. Particles of respirable size are generally not encountered. The respirable fraction for the tablet active ingredient is typically less than 0.1% by weight for the granular and extra granular grades. If it is ground or otherwise in a powdered form, effects similar to a corrosive substance may occur. May cause severe irritation of the respiratory tract with coughing, choking, pain and possibly burns of the mucous membranes. If significant or prolonged exposure occurs, pulmonary oedema may develop, either immediately or more often within a period of 5-72 hours. The symptoms may include tightness in the chest, dyspnea, frothy sputum, cyanosis, and dizziness. Physical findings may include moist rales, low blood pressure and high pulse pressure. Severe cases may be fatal. Eyes: This material is corrosive to the eye. Direct contact may cause severe irritation, pain and burns, possibly severe, and permanent damage including blindness. The degree of injury depends on the concentration and duration of contact. Skin: This material is corrosive to the skin. Direct contact with wet material or moist skin may cause severe irritation, pain, and possibly burns. Dry material is less irritating than wet material. This material is not a skin sensitiser based on studies with guinea pigs. Ingestion: Not a likely route of exposure. Harmful if swallowed. Ingestion may cause immediate pain and severe burns of the mucous membranes. There may be discoloration of the tissues. Swallowing and speech may be difficult at first and then almost impossible. The effects on the oesophagus and gastrointestinal tract may range from irritation to severe corrosion. Oedema of the epiglottis and shock may occur. Repeated Exposure (Chronic) Based on animal studies, exposure to concentrations of monosodium cyanurate at the solubility limit may cause cardiovascular, kidney and urinary bladder effects.

Medical Conditions Generally Aggravated by Exposure

eye disorders, respiratory disorders, skin disorders and allergies TARGET ORGANS: cardiovascular system, kidneys, bladder.

PBT Substances

The substances contained in this preparation are not identified as PBT substances